WA
ALXN

WESPAC Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

WESPAC Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,422
Closed -$217K – 178
2021
Q1 		$217K Buy
+1,422
New +$220K 0.16% 153

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

WESPAC Advisors's ALXN Position: Q2 2021 in Review

WESPAC Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 1,422 shares — an estimated $217K sold.

WESPAC Advisors first reported a position in ALXN in Q1 2021 and held it in 1 quarter. The position peaked at $217K in Q1 2021. 707 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • WESPAC Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • WESPAC Advisors sold 1,422 Alexion Pharmaceuticals shares in Q2 2021, an estimated $217K.
  • WESPAC Advisors first reported a position in Alexion Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • WESPAC Advisors's Alexion Pharmaceuticals position peaked at $217K in Q1 2021.
  • 707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on WESPAC Advisors's 13F filing for Q2 2021, filed 3 Aug 2021.